SHARE CAPITAL |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| SHARE CAPITAL |
Authorized
Unlimited number of subordinate voting shares without par value.
Issued
As at March 31, 2026, subordinate voting shares were issued and outstanding.
During the three months ended March 31, 2026
On March 30, 2026, the Company issued subordinate voting shares to the Vendor (See note 4)
FEMTO TECHNOLOGIES INC. Notes to the Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2026 (Expressed in Canadian dollars) (Unaudited)
NOTE 8 – SHARE CAPITAL (continued)
During the three months ended March 31, 2025
On January 3, 2025, the Company issued subordinate voting shares ( subordinate voting shares post reverse split) following the exercise of B warrants.
On January 6, 2025, the Company issued subordinate voting shares ( subordinate voting shares post reverse split) following the exercise of B warrants.
On February 7, 2025, the Company issued subordinate voting shares ( subordinate voting shares post reverse split) to directors and consultants of the Company following the vesting of RSU’s.
On February 25, 2025, the Company issued subordinate voting shares ( subordinate voting shares post reverse split) following the exercise of B warrants and subordinate voting shares ( subordinate voting shares post reverse split) following the exercise of A warrants.
On February 28, 2025, the Company announced the closing of a Private Placement with gross proceeds to the Company of approximately of $ before deducting Agent placement commission and other expenses paid by the Company in the amount of $, totaling in a net amount of $. Pursuant to the Private Placement, The Company issued subordinate voting shares ( subordinate voting shares post reverse split), Pre-Funded Warrants, series A warrants and series B warrants. See note 10 for a discussion of the terms of the series A and B warrants.
Stock options
The Company has a stock option plan to grant incentive stock options to directors, officers, employees and consultants. Under the plan, the aggregate number of subordinate voting shares that may be subject to option at any one time may not exceed 30% of the issued subordinate voting shares of the Company as of that date, including options granted prior to the adoption of the plan. The exercise price of these options is not less than the Company’s closing market price on the day prior to the grant of the options. Options granted .
As of March 31, 2026, and 2025 there were stock options outstanding.
|